Business Context and Reporting Period
Company: Tivic Health Systems, Inc. (Note: Input metadata referenced "Valion Bio, Inc.", but the filing text identifies the registrant as Tivic Health Systems, Inc., trading as TIVC).
Filing Type: Form 8-K (Current Report)
Date of Report: December 9, 2025
Reporting Period: Events occurring on December 9, 2025, with transaction closings on December 10, 2025.
Business Overview: The Company is a biopharmaceutical firm developing Entolimod, a TLR5 agonist for acute radiation syndrome. The filing details a strategic pivot to bring manufacturing in-house by acquiring the assets of its former contract manufacturer, Scorpius Holdings, Inc., following Scorpius's default on secured notes.
Key Financial Metrics and Transactions
The filing does not provide historical revenue, profit, or cash flow statements. It focuses on three major capital transactions executed on December 9, 2025:
- Asset Acquisition: Acquired all personal property and assets of Scorpius Holdings, Inc. (including CDMO facilities, equipment, and IP) for $16,253,147.10 in cash. No liabilities were assumed.
- Senior Secured Convertible Note Offering: Issued a note to 3i, LP with a principal amount of $16,253,147.10.
- Interest Rate: 5.0% per annum (10% upon default).
- Maturity: 5 years from issuance.
- Conversion Price: $2.2310 (subject to floor price of $0.39 and anti-dilution adjustments).
- Warrants: Issued warrants to purchase up to 4,553,213 shares of common stock.
- Preferred Stock Offering: Agreed to sell up to 75,000 shares of Series C Non-Voting Convertible Preferred Stock for up to $75,000,000 in tranches.
- Initial Tranche: 12,000 shares sold for $12,000,000 (closed Dec 10, 2025).
- Price: $1,000 per share (Stated Value $1,080).
- Dividends: 6% cumulative annual rate (payable in cash or PIK).
- Warrants: Issued warrants equal to 50% of shares issuable upon conversion of the preferred stock.
Material Changes and Strategic Shifts
- Manufacturing Vertical Integration: The acquisition of Scorpius assets allows Tivic to transition from a contract manufacturing model to in-house production for Entolimod and potentially offer CDMO services to third parties.
- Capital Structure Restructuring: The Company terminated its Equity Purchase Agreement with Mast Hill Fund, L.P. and replaced it with the new Note and Preferred Stock financings with 3i, LP and institutional investors.
- Debt Assumption: 3i, LP assumed the rights and obligations of Helena Global Investment Opportunities I Ltd. regarding the April 2025 Securities Purchase Agreement (Series B Preferred Stock), extending the termination date to December 9, 2026.
Guidance, Risks, and Contingencies
- Stockholder Approval Requirement: The Note Offering and Preferred Offering are subject to an "Exchange Cap" limiting issuance to 19.99% of outstanding common stock. The Company must hold a special stockholder meeting within 90 days to waive this cap to fully utilize the financing.
- Management Rights Trigger: Holders of Series C Preferred Stock may appoint one or two directors to the Board if the Company's net monthly cash burn exceeds the Board-approved Maximum Cash Burn by more than 15% for two consecutive fiscal quarters.
- Restricted Period: The Company is prohibited from entering into variable rate transactions or issuing new equity for 12 months (or until less than 10% of the Note principal remains outstanding).
- Financial Statement Filing: The Company is still determining if the acquisition requires the filing of financial statements or pro forma information under Item 9.01; if required, these will be filed within 71 days.
- Asset Condition: The Scorpius assets were purchased "as is" with no representations, warranties, or indemnities from the seller (3i, LP as Collateral Agent).
Investor Verification Checklist
- Verify the outcome of the stockholder meeting required to waive the 19.99% Exchange Cap, as this limits the full conversion of the Note and Preferred Stock.
- Confirm the Company's current cash burn rate against the "Maximum Cash Burn" threshold to assess the risk of investor-appointed directors.
- Review the status of the remaining tranches of the $75 million Preferred Offering, which are contingent on specific volume and price conditions.
- Monitor the filing of Item 9.01 financial statements regarding the Scorpius acquisition to assess the fair value of assets acquired.
- Check for any future equity issuances that might trigger the "Base Conversion Price" adjustment, lowering the conversion price of the Note and Preferred Stock.